A large number of small molecules in development and about 40% of marketed products are sparingly to practically insoluble in water. Poor water solubility of small molecules limits its absorption and/or bioavailability in the human body. MAA’s NanoCont™ technology improves the solubility of a large range of particle sizes through the use of a patented polymer coating for enhanced solubility and/or targeted drug delivery. Improved solubility and targeted delivery allow reduced dosing, which overcomes the current challenges of higher dose administration, mitigates side effects and/or undesirable effects, as well as inter- and intra- patient dose variability. MAA has identified the lead candidates in the areas listed below to create new products from the existing small molecules to increase therapeutic efficiency (low dose), mitigate side effects/undesirable effects, and reduce product manufacturing time significantly.
Products in Development Therapeutic Area Indication
MAAC-001 Oncology Cancer
MAAC-002 Oncology Leukemia
MAAC-003 Oncology Renal Cell Carcinoma
MAAC-004 Oncology Prostate